dipeptidyl
peptidaseiv
singlepass
type
ii
transmembran
glycoprotein
best
known
role
catalyt
inactiv
incretin
hormon
glucagonlik
gastric
inhibitori
polypeptid
gip
addit
catalyt
function
interact
number
ligand
adenosin
deaminas
ada
middl
east
respiratori
syndrom
coronaviru
merscov
spike
protein
fibronectin
thought
play
import
role
mediat
inflamm
addit
cell
surfac
membranebound
form
also
exist
cleav
catalyt
activ
extracellular
domain
circul
plasma
highli
express
cell
monocyt
antigenpres
cell
adipos
tissu
associ
cellmedi
inflamm
addit
increas
obes
patient
express
posit
correl
degre
insulin
resist
membran
bound
hematopoiet
adipocyt
may
contribut
substanti
proport
plasma
implic
cell
type
act
import
regul
incretin
action
studi
team
group
suggest
import
role
immun
cellexpress
diabet
cardiovascular
diseas
howev
mechan
mediat
express
cell
poorli
understood
given
central
role
monocytemacrophag
atherosclerosi
recent
report
express
monocyt
plasma
activ
increas
patient
atherosclerosi
posit
correl
atherosclerot
plaqu
volum
addit
express
level
monocyt
also
associ
plasma
level
nonhdl
cholesterol
triglycerid
howev
mechan
upregul
cardiometabol
diseas
remain
elucid
studi
found
treatment
oxid
lowdens
lipoprotein
oxldl
nativ
ldl
elev
express
macrophag
attenu
inhibit
tolllik
receptor
downstream
domaincontain
adaptorinduc
trif
express
almost
exclus
occur
monocyt
defici
macrophag
show
attenu
upregul
respons
oxldl
first
time
knowledg
find
demonstr
import
role
oxid
lipid
immun
cell
regul
may
provid
integr
mechan
link
abnorm
postprandi
glucos
metabol
oxid
lipid
inflamm
procedur
studi
approv
institut
review
board
irb
ohio
state
univers
case
western
reserv
univers
written
inform
consent
obtain
particip
studi
total
patient
previous
document
cardiovascular
diseas
enrol
alpin
trial
includ
studi
alpin
phase
clinic
trial
clinicaltrialsgov
identifi
describ
elsewher
patient
establish
cardiovascular
diseas
recruit
columbu
ohio
random
receiv
either
placebo
aliskiren
treatment
cardiovascular
diseas
defin
least
follow
myocardi
infarct
cerebrovascular
accid
previou
coronari
arteri
bypass
graft
surgeri
andor
percutan
coronari
intervent
peripher
arteri
diseas
anklebrachi
index
andor
prior
peripher
intervent
surgeri
homair
calcul
follow
homair
fast
serum
glucos
mgdl
fast
plasma
insulin
patient
one
follow
condit
exclud
studi
histori
malign
diagnosi
type
diabet
use
hypoglycem
drug
uncontrol
hypertens
mmhg
renal
insuffici
defin
glomerular
filtrat
rate
mlmin
deriv
modifi
diet
renal
diseas
equat
unstabl
cardiac
syndrom
data
atherosclerot
patient
within
placebo
group
reanalyz
fourteen
age
racematch
healthi
volunt
without
cardiovascular
diseas
defin
serv
control
biolog
marker
includ
fast
blood
glucos
fast
insulin
glycosyl
hemoglobin
leptin
adiponectin
total
cholesterol
hdl
cholesterol
ldl
cholesterol
ldlc
triglycerid
systol
blood
pressur
sbp
diastol
blood
pressur
sbp
stand
heart
rate
hr
bodi
mass
index
bmi
blood
urea
nitrogen
creatinin
creatinin
kinas
uric
acid
albumin
total
protein
alkalin
phosphatas
sodium
potassium
chlorid
examin
clinic
laboratori
peripher
blood
mononuclear
cell
pbmc
isol
human
peripher
blood
densiti
gradient
centrifug
use
ficol
brief
blood
collect
edtaco
tube
dilut
steril
pb
layer
ficollpaqu
plu
ge
healthcar
piscataway
nj
follow
centrifug
min
without
appli
brake
pbmc
interfac
care
remov
wash
twice
pb
pbmc
place
plate
h
adher
cell
monocyt
cultur
medium
supplement
fb
ngml
recombin
human
macrophag
colonystimul
factor
r
minneapoli
mn
day
media
replac
day
human
plasma
isol
edta
anticoagul
peripher
blood
centrifug
g
min
enzymat
activ
plasma
measur
use
proteas
assay
kit
promega
madison
wi
follow
manufactur
instruct
mice
purchas
jackson
laboratori
procedur
approv
iacuc
committe
case
western
reserv
univers
antibodi
use
flow
cytometri
purchas
follow
compani
antihuman
clone
pelabel
purchas
ebiosci
san
diego
ca
clone
apclabel
purchas
biolegend
san
diego
ca
pelabel
antimous
clone
r
system
minneapoli
mn
antihuman
clone
pe
apclabel
biolegend
san
diego
ca
apclabel
antimous
clone
ebiosci
san
diego
ca
antihumanmous
clone
biolegend
san
diego
ca
fitclabel
antihuman
clone
ebiosci
san
diego
ca
antihuman
clone
ebiosci
san
diego
ca
antihuman
clone
ebiosci
san
diego
ca
oxid
ldl
purchas
thermo
fisher
scientif
cat
thermo
fisher
scientif
waltham
enzymat
inhibitor
linagliptin
kind
gift
boehring
ingelheim
ingelheim
rhein
germani
obtain
bone
marrowderiv
macrophag
bmm
bone
marrow
cell
isol
mous
tibia
femur
cultur
fb
ngml
recombin
mous
mcsf
r
system
minneapoli
mn
day
media
replac
everi
day
adher
bmm
use
experi
day
antibodi
use
imag
flow
cytometri
purchas
biolegend
san
diego
ca
bd
san
jose
ca
r
system
minneapoli
mn
cell
stain
indic
antibodi
describ
elsewher
analyz
either
imag
cytomet
amni
seattl
wa
lsrii
flow
cytomet
bd
san
jose
ca
data
studi
present
mean
standard
error
mean
se
p
valu
consid
statist
signific
graphpad
prism
use
statist
analysi
use
student
ttest
anova
analysi
boneferroni
post
hoc
test
linear
regress
appropri
patient
miss
data
exclud
analysi
import
regul
incretininsulin
axi
express
number
immun
cell
role
global
diabet
cardiovascular
diseas
well
studi
function
immun
cellderiv
cardiometabol
diseas
remain
elucid
determin
role
immun
cellexpress
cardiovascular
diseas
first
examin
express
circul
immun
cell
use
imag
flow
cytometri
result
indic
monocyt
cell
major
popul
express
human
peripher
blood
major
granulocyt
b
cell
express
fig
addit
membranebound
also
cleav
cell
membran
present
solubl
form
plasma
next
detect
enzymat
activ
membranebound
white
blood
cell
solubl
plasma
result
leukocyt
contribut
consider
enzymat
activ
circul
fig
examin
immun
cell
also
contribut
gener
solubl
plasma
knockout
mice
irradi
transplant
wildtyp
wt
bone
marrow
plasma
isol
detect
activ
week
depict
fig
mice
wt
bone
marrow
show
significantli
higher
level
plasma
activ
compar
bone
marrow
suggest
immun
cell
contribut
gener
solubl
addit
enzymat
inhibit
inhibitor
week
increas
express
macrophag
fig
suggest
may
neg
feedback
loop
control
express
enzymat
activ
monocyt
macrophag
central
effector
innat
immun
recogn
key
pathophysiolog
player
develop
variou
chronic
condit
atherosclerosi
recent
studi
indic
express
circul
monocyt
increas
atherosclerosi
associ
atherosclerot
burden
sinc
upregul
associ
obes
divid
patient
two
group
obes
bmi
nonobes
bmi
biolog
characterist
marker
shown
tabl
signific
differ
age
sbp
dbp
hr
biochem
paramet
aspart
transaminas
ast
alanin
transaminas
alt
creatinin
creatin
kinas
alkalin
phosphatas
albumin
sodium
potassium
chlorid
blood
urea
nitrogen
total
protein
level
homair
nonhdl
cholesterol
uric
acid
triglycerid
fast
blood
glucos
fast
insulin
leptin
significantli
increas
adiponectin
level
lower
obes
patient
atherosclerosi
tabl
given
oxid
modifi
cholesterol
fundament
pathogenesi
atherosclerosi
wide
believ
repres
plausibl
mechan
acceler
atherosclerosi
insulin
resistancetyp
diabet
test
effect
ldl
nativ
oxid
regul
express
treatment
lipoprotein
either
nativ
ldl
oxldl
express
bone
marrow
deriv
macrophag
bmm
mice
detect
flow
cytometri
result
show
treatment
nativ
ldl
affect
express
macrophag
contrast
oxldl
significantli
increas
frequenc
macrophag
vs
vs
untreat
vs
nativ
ldl
vs
oxldl
respect
fig
addit
percentag
chang
express
increas
macrophag
evidenc
fact
mfi
cell
higher
oxldltreat
group
vs
vs
untreat
vs
nativ
ldl
vs
oxldl
respect
fig
dose
respons
experi
reveal
oxldl
dosedepend
enhanc
express
macrophag
supplement
fig
similar
find
observ
periton
macrophag
mice
fig
furthermor
upregul
follow
oxldl
treatment
accompani
increas
express
inflammatori
cytokin
fig
also
trend
increas
express
two
import
compon
inflammasom
complex
respons
matur
fig
confirm
result
human
prepar
monocytederiv
macrophag
mdm
human
peripher
blood
monocyt
treat
cell
oxldl
oxldl
increas
express
human
macrophag
nearli
two
fold
fig
next
examin
oxid
cholesterol
import
compon
oxldl
could
induc
upregul
interestingli
significantli
upregul
treatment
suggest
upregul
may
mediat
free
form
oxid
cholesterol
supplement
fig
activ
may
occur
bind
atherogen
lipid
receptor
provid
proxim
signal
event
requir
proinflammatori
mediat
chemokin
inflammasom
activ
er
stress
therefor
initi
examin
depend
proxim
trigger
induct
induc
activ
lipopolysaccharid
lp
stimul
examin
express
lp
enhanc
express
human
monocyt
sirnamedi
knockdown
substanti
abrog
lpsinduc
upregul
fig
trif
two
main
downstream
molecul
mediat
signal
test
upregul
depend
major
adaptor
molecul
signal
bone
marrow
cell
isol
wildtyp
wt
mice
use
induct
bmm
express
wt
bmm
increas
treatment
oxldl
howev
defici
diminish
upregul
contrast
even
slight
increas
express
oxldl
treatment
bmm
fig
use
mice
examin
involv
pathway
mediat
express
compar
wt
bmm
bmm
show
impair
upregul
follow
oxldl
treatment
although
complet
abolish
oxldlinduc
upregul
fig
sinc
tlr
may
mediat
oxldlinduc
inflammatori
respons
cooper
next
test
involv
mous
macrophag
costain
approxim
periton
macrophag
express
popul
gate
analysi
express
macrophag
express
macrophag
express
high
level
fig
oxldl
treatment
frequenc
macrophag
increas
express
also
coordin
increas
within
cell
supplement
fig
similar
find
also
observ
human
mdm
fig
confirm
depend
upregul
wt
bmm
treat
oxldl
express
measur
expect
bmm
decreas
express
treatment
oxldl
compar
wt
bmm
fig
suggest
requir
oxldlinduc
upregul
taken
togeth
oxldl
upregul
express
monocyt
macrophag
via
pathway
fig
paper
demonstr
import
role
pathway
regul
monocytemacrophag
lineag
express
macrophag
demonstr
heterogen
express
high
level
seen
cell
oxldl
markedli
upregul
express
via
pathway
result
suggest
import
role
oxid
lipid
inflammatori
signal
regul
may
provid
integr
mechan
link
abnorm
postprandi
glucos
metabol
oxid
lipid
inflamm
prior
studi
shown
express
markedli
increas
surfac
antigen
present
cell
apc
macrophag
dendrit
cell
viscer
adipos
obes
human
level
express
apc
posit
correl
degre
insulin
resist
line
find
sell
et
al
also
confirm
upregul
adipos
tissu
obes
insulin
resist
subject
adipos
tissu
correl
measur
insulin
resist
inflamm
find
clearli
implic
markermedi
inflamm
adipos
tissu
experiment
studi
strongli
demonstr
role
progress
atherosclerosi
increas
express
proinflammatori
monocytesmacrophag
plaqu
howev
given
rel
neutral
recent
trial
catalyt
inhibitor
role
question
one
potenti
reason
lack
efficaci
studi
may
relat
diverg
rolefunct
catalyt
versu
noncatalyt
function
particularli
cell
type
monocyt
cell
thu
investig
focus
express
membran
bound
atherosclerosi
previous
shown
macrophag
dendrit
cell
may
enhanc
adipos
tissu
inflamm
via
noncatalyt
pathway
recent
studi
ghorpad
et
al
also
report
act
plasma
factor
xa
inflam
adipos
tissu
macrophag
silenc
express
hepatocyt
enzymat
inhibit
sitagliptin
reduc
adipos
tissu
inflamm
insulin
resist
current
studi
observ
catalyt
inhibit
increas
express
macrophag
result
indic
compensatori
upregul
catalyt
inhibit
may
promot
inflamm
could
possibl
explan
neutral
effect
inhibitor
cardiovascular
outcom
larg
crosssect
studi
china
plasma
activ
shown
correl
carotid
intima
media
thick
activ
studi
associ
posit
degre
insulin
resist
homair
oxid
ldl
measur
oxid
stress
includ
nitrotyrosin
interestingli
recent
studi
indic
correl
plasma
activ
atherosclerosi
suggest
catalyt
activ
circulatingsolubl
alon
may
suffici
serv
mediat
atherosclerosi
addit
one
could
conclud
monocyt
may
import
sourc
circul
inde
adipocyt
endotheli
cell
bone
marrow
deriv
cell
monocyt
confirm
import
sourc
circul
previous
shown
monocyt
express
posit
associ
nonhdl
cholesterol
triglycerid
fast
blood
glucos
insulin
level
suggest
increas
monocyt
obes
patient
might
relat
dysregul
lipid
metabol
insulin
resist
sinc
ldl
oxid
modifi
form
highli
preval
atherosclerosi
may
link
diabet
acceler
atherosclerosi
examin
effect
nativ
ldl
oxldl
express
interestingli
oxldl
nativ
ldl
free
form
oxid
cholesterol
enhanc
express
macrophag
addit
upregul
express
also
upregul
follow
oxldl
treatment
accompani
trend
increas
inflammasom
compon
result
consist
previou
report
recent
studi
demonstr
may
coordin
tlr
enhanc
oxldlinduc
inflammasom
activ
atherosclerosi
howev
causal
relationship
upregul
product
examin
studi
requir
investig
activ
tlr
downstream
inflammatori
signal
could
activ
excess
free
fatti
acid
low
densiti
lipoprotein
apolipoprotein
ciii
lipoprotein
oxid
addit
express
activ
tlr
also
report
increas
patient
metabol
syndrom
line
previou
find
found
knockdown
defici
downstream
molecul
trif
abolish
oxldlmedi
upregul
macrophag
suggest
oxldlinduc
signal
may
respons
elev
monocyt
obes
trif
two
major
downstream
adaptor
protein
tlr
present
studi
found
trif
rather
requir
oxldlinduc
upregul
trif
respons
mediat
activ
product
mediat
studi
oxldlinduc
upregul
even
slightli
enhanc
defici
macrophag
could
result
compensatori
enhanc
trif
signal
knockout
macrophag
role
trif
signal
atherosclerosi
complex
depend
cellular
context
upstream
pathway
trif
could
proatherogen
atheroprotect
lossoffunct
mutat
trif
improv
atherosclerosi
mice
defici
mice
enhanc
atherosclerosi
develop
sinc
trif
signal
primarili
induc
data
suggest
trif
signal
promot
atherosclerosi
trif
respons
may
atheroprotect
howev
anoth
studi
report
signal
bone
marrow
cell
proatherogen
effect
mice
studi
ohnuma
suggest
may
induc
activ
monocyt
matur
interact
therefor
upregul
oxldlinduc
innat
signal
may
turn
activ
inflammatori
signal
result
feedforward
loop
stewart
et
al
previous
report
tlr
cooper
mediat
oxldlinduc
inflammatori
respons
wellknown
scaveng
receptor
respons
oxldl
uptak
foam
cell
format
found
studi
also
involv
oxldlinduc
upregul
almost
cell
also
express
treatment
oxldl
increas
express
consist
previous
report
find
addit
defici
least
partial
abolish
oxldlinduc
upregul
find
suggest
import
role
oxldlinduc
upregul
acknowledg
number
import
limit
studi
importantli
demonstr
link
mediat
triglycerid
postprandi
remnant
remnant
lipoprotein
markedli
increas
diabet
dyslipidemia
may
repres
fraction
could
potenti
particip
link
disord
lipid
metabol
postprandi
state
abnorm
glucos
metabol
addit
acknowledg
express
human
monocyt
examin
larg
sampl
patient
howev
one
critic
find
human
studi
increas
obes
atherosclerosi
support
report
larger
popul
size
also
provid
addit
mechan
link
chang
express
downstream
activ
trif
kinas
pathway
may
function
upstream
conclus
demonstr
role
oxid
lipid
mediat
upregul
atherosclerosi
via
depend
pathway
data
provid
link
disord
lipid
metabol
atherosclerosi
impair
glucos
intoler
upregul
